 "Ajanta Pharma receives US FDA approval for antidepressant drug duloxetine")
Ajanta Pharma Limited has received the final approval for duloxetine hydrochloride delayed release capsule, which is a generic version of Eli Lilly & Co’s Cymbalta, from US Food & Drug Administration (FDA). The company plans to launch the product shortly in 3 strengths, 20 mg, 30 mg and 60 mg strengths capsules.
Cymbalta (duloxetine), which is a selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI), is mostly prescribed for major depressive disorder, generalised anxiety disorder, fibromyalgia and neuropathic pain.
Duloxetine hydrochloride delayed release capsule is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 32 abbreviated new drug applications (ANDAs) of which it has 17 final ANDA approvals, 2 tentative approvals and 13 ANDAs under review with US FDA.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%